French immunodiagnostics SME developing molecular assays and immune profiling tools for cancer patient stratification and immunotherapy selection.
HalioDx (now operating under the Veracyte brand following a 2021 acquisition) is a French immunodiagnostics SME specializing in tumor microenvironment profiling and immune-based cancer diagnostics. They develop in vitro diagnostic tests and molecular assays that characterize the immune context of tumors — enabling clinicians and researchers to stratify patients by molecular subtype and predict response to treatment. In EU research consortia, they contribute commercial-grade assay development, patient sample analysis, and the translation of multi-omics research findings into clinically deployable diagnostic tools. Their core value in any consortium is bridging the gap between academic cancer biology and real-world diagnostic product development.
Both COLOSSUS and ONCOBIOME rely on their immunomics and molecular fingerprinting capabilities to characterize the immune landscape of tumors across colorectal, breast, melanoma, and lung cancer.
ONCOBIOME keywords explicitly include 'in vitro diagnostic', 'diagnosis tests', and 'assays', reflecting their role as the diagnostic product development partner in research consortia.
COLOSSUS is explicitly focused on systems-based patient stratification in metastatic colorectal cancer using multi-omics and molecular subtype classification.
COLOSSUS keywords include multi-omics, systems medicine, and computational models, indicating they contribute data and expertise to bioinformatics-heavy research pipelines.
ONCOBIOME (2019–2025) introduced microbiome as a new diagnostic dimension, with keywords covering prophylactic measures, molecular fingerprints, and cancer incidence prediction.
Their initial H2020 engagement (COLOSSUS, 2018) was tightly focused on colorectal cancer and RAS mutations, applying immunomics and systems medicine to crack patient stratification in a single cancer type. By 2019 (ONCOBIOME), the scope expanded dramatically to cover breast cancer, melanoma, lung cancer, and colon cancer simultaneously — and added the gut microbiome as an entirely new axis of cancer biology alongside immunotherapy prediction and prophylaxis. The shift signals a deliberate move from organ-specific depth to a pan-cancer diagnostic platform capable of integrating immune, molecular, and microbial data streams.
They are building toward multi-cancer immune and microbiome profiling platforms, positioning themselves as a diagnostic partner for immunotherapy patient selection across tumor types — a high-growth area as immunotherapy adoption expands in oncology.
HalioDx/Veracyte exclusively joins consortia as a participant, never as a coordinator — a pattern consistent with a specialist SME that contributes diagnostic and assay expertise rather than driving research agendas. Despite only two projects, they have accumulated 33 unique consortium partners across 12 countries, which means they operate in very large, multi-institutional research networks. This suggests they are comfortable as one specialist node among many, and that consortium leaders actively seek them out for their commercial diagnostics capabilities.
With 33 unique partners across 12 countries from just two projects, their per-project network density is high — each project involves roughly 16 partner organizations spanning multiple European countries. Their network is likely concentrated in oncology research institutions, clinical trial networks, and biomarker consortia.
As an industry SME in a landscape otherwise dominated by universities and research institutes, HalioDx/Veracyte brings something most consortium partners cannot: the capacity to take a research biomarker and move it toward a validated, commercially deployable diagnostic assay. This makes them particularly valuable in RIA consortia that need an industry translation partner to satisfy impact and exploitation requirements. Their position within the Veracyte group (a US-listed precision diagnostics company) also means they carry global commercialization reach that a standalone SME would not.
